Onchocerciasis Clinical Trial
Official title:
A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection
The purpose of this study is to measure the amount of moxidectin in subjects' blood and to measure safety. This study will enroll 36 children aged 4 to 11 years (>=12 kg) with or without Onchocerca volvulus (O volvulus) infection. O volvulus is the nematode, or roundworm, that causes Onchocerciasis, also known as river blindness. Each subject will receive a single dose of 4 mg moxidectin (orally administered) and will be followed inpatient from screening through day 13 and as outpatients through month 6. The study will take place at a single research center.
n/a
Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00300768 -
Study Evaluating Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection
|
Phase 2 | |
| Not yet recruiting |
NCT04035174 -
Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
|
N/A | |
| Recruiting |
NCT03653975 -
Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District
|
||
| Completed |
NCT03052998 -
Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy
|
Phase 4 | |
| Recruiting |
NCT04311671 -
Safety of a Single Dose of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas and in Individuals Living in Onchocerciasis Endemic Areas With High Levels of Lymphatic Filariasis Co-endemicity Receiving Concomitant Albendazole
|
Phase 3 | |
| Active, not recruiting |
NCT03876262 -
Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis
|
Phase 3 | |
| Terminated |
NCT04913610 -
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-4083 Capsules When Given Alone or In Combination With Albendazole Capsules Moves in The Body of Adult Participants With Onchocerca Volvulus Infection
|
Phase 2 | |
| Completed |
NCT03962062 -
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
|
Phase 1 | |
| Completed |
NCT01905436 -
Mass Drug Administration for Lymphatic Filariasis and Onchocerciasis for Liberia
|
||
| Recruiting |
NCT00001230 -
Host Response to Infection and Treatment in Filarial Diseases
|
||
| Completed |
NCT05750043 -
Effect of Onchocerciasis Elimination Measures on the Incidence of Epilepsy in Maridi, South Sudan
|
||
| Completed |
NCT05749653 -
Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area
|
N/A | |
| Completed |
NCT02078024 -
Efficacy of Ivermectin and Albendazole Against Onchocerciasis in the Volta Region, Ghana
|
Phase 3 | |
| Completed |
NCT00127504 -
Clinical Trial of Rifampin and Azithromycin for the Treatment of River Blindness
|
Phase 2 | |
| Completed |
NCT03131401 -
Prevalence of LF Infection in Districts Not Included in LF Control Activities
|
||
| Not yet recruiting |
NCT06070116 -
Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis
|
Phase 2 | |
| Completed |
NCT02032043 -
Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast (DOLF-Ivory Coast)
|
||
| Completed |
NCT04188301 -
Safety and Efficacy of IDA for Onchocerciasis
|
Phase 2 | |
| Terminated |
NCT05084560 -
Development of AWZ1066S, a Small Molecule Anti-Wolbachia Candidate Macrofilaricide Drug
|
Phase 1 | |
| Completed |
NCT03517462 -
Ocular Changes After Ivermectin - (DOLF IVM/Oncho)
|
N/A |